Four biotechs raised more than $1.2 billion in a strong IPO run, continuing a 2026 wave in which investors have shown renewed appetite for public offerings. The broader data point cited in the report tracks 20 NASDAQ biotech IPOs raising a combined $6.9 billion this year, with many debuting above issue price. At the company level, the market momentum is consistent with oversized offerings across multiple sub-areas, including oncology and non-opioid pain—categories where investors are underwriting clear clinical narratives and late-stage catalysts. The report frames the IPO market as “strong,” with first-day gains for the majority of recent listings. For biotech leadership teams, the message is timing: window openings in public markets can change capital structure options quickly, impacting runway and trial design decisions well before major readouts.